Adjuvant therapy for colon cancer - The pace quickens

New England Journal of Medicine

Volumn 352, Issue 26, 2005, Pages 2746-2748

  Allegra, Carmen ^a   Sargent, Daniel J ^b  

^a Network for Medical Communication and Research   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; VACIZUMAB; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; EDITORIAL; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LYMPH NODE METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLON TUMOR; DISEASE FREE SURVIVAL; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; NEOPLASM STAGING;

EID: 21244462421     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058117     Document Type: Editorial

References (15)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
2. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-806.
3. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
4. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
5. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
6. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005;23:1819-25.
7. André T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21:2896-903.
8. Mayo Clinic. 3 Year DFS vs. 5 year OS as an endpoint for adjuvant colon cancer studies: data from randomized trials. (Accessed June 9, 2005, at http://www.fda.gov/cder/drug/cancer_endpoints/Sargent/ index.htm.)
9. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
11. Wolmark N, Wieand JP, Kuebler L, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07. J Clin Oncol 2005;23:Suppl: 252s. abstract.
12. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts): (PETACC 3). J Clin Oncol 2005;23: Suppl:3s. abstract.
13. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovorin (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 2004;22:Suppl:245s. abstract.
14. Gray RG, Barnwell J, Hills R, et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol 2004;22:Suppl:246s. abstract.
15. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;35:337-45.